Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Post by jopatcloon Jan 22, 2025 9:01am
37 Views
Post# 36414792

Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀

Us2.ai !🤔👀 Ventripoint integrated into Ascend's Gen3Echo🚀Interesting on Linkedin see video a 5.20 on Us2.ai &remember on website Ascend  Ventripoint integrated into Ascend's Gen3Echo...The BEST automation and analysis of the PLANET GEN3EHO On Ascend website https://ascendcv.com/ .

 https://www.cnbc.com/advertorial/the-quiet-revolution/?__source=linkedin|catalyst|esg
A heartfelt thank you to CNBC and Enterprise Singapore for featuring Us2.ai’s solution in this inspiring project spotlighting innovative technologies addressing global healthcare challenges.

With cardiovascular disease remaining the leading cause of mortality worldwide, at Us2.ai, our mission is to improve patient outcomes and expand healthcare access by democratizing echocardiograms—the most widely used tool for detecting heart risks—through the power of AI.

We envision a future where high-quality, consistent, and affordable echocardiogram analysis is accessible to everyone, from the most tech-advanced regions to resource-constrained communities worldwide.

At Us2.ai, we are proud to be transforming the landscape for early detection of cardiovascular diseases.

Contact us to learn more about how our solution can make a difference!

AI EchoFirst Innovation Cardiology PatientsFirst AIEcho
remember see on website 

Seamless, flexible integration with heterogeneous AI, imaging and enterprise IT environments enables a best-of breed approach. Examples include:

  • Us2.ai - Benefit from the the industry’s most sophisticated integration of Us2.ai.
    • Us2.ai FDA-approved measurements feed ASE-validated suggested interpretations that can automatically complete the echo report 
    • Save time with single-click navigation to the automated measurement source frame 
    • 1-click sync to automated measurement frame
    • Distinct review processes for FDA-cleared versus investigational measurements, enhancing compliance and clarity 
    • Automatic grouping of Us2.ai measurements accelerates the measurement review process 
    • Visual notification of user edits performed on Us2.ai measurements promotes transparency and traceability 
  • Engineered for seamless integration: Gen3Echo was designed with commitment to openness, seamlessly integrating with AI, ML, and advanced visualization software to foster innovation and collaboration. 
    • Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patients. Ventripoint’s VMS product is powered by its proprietary KBR technology and provides accurate volumetric cardiac measurements with sMRI levels of accuracy. It can be used with all ultrasound systems supported by regulatory market approvals and is seamlessly integrated into the reading workflow enhancing diagnostic precision and treatment planning, ultimately improving the quality of pediatric care.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities